More Mesoblast Limited news
Mesoblast LimitedASX: MSB

Increased Survival Using MSB Cells In Children With aGVHD

Feb 21, 2016 at 11:09 PM EST · Issued by Mesoblast Limited

Filed with ASX · Feb 21, 2016 at 11:09 PM EST · 2 pages · English

On 6ix: 6ix.com/news/increased-survival-using-msb-cells-in-children-with-agvhd

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • Improved Survival in Children with GvHD After Cell TherapyFeb 11, 2016
  • Results Show Improved Survival in Children with GVHDFeb 11, 2016

Earlier from Mesoblast

  • Half Yearly Report and Accounts (including Appendix 4D)Feb 16, 2016
  • MSB Therapy Shows Benefit In First Cohort Of RA PatientsFeb 15, 2016
  • Phase 3 Heart Failure Trial Size Substantially ReducedFeb 11, 2016
  • US Govt Grants for Further Development of Stem Cell ProductsFeb 10, 2016
  • USA FDA Clears Phase 2 Trial For Cervical Spinal FusionFeb 10, 2016

Later from Mesoblast

  • GVHD Product Launched In JapanFeb 24, 2016
  • Key US Patent Granted For Treatment Of Rheumatoid ArthritisMar 23, 2016
  • Circulation Publishes Improved Outcomes with Mesoblast CellsMar 30, 2016
  • Mesoblast Receives $5.05m for Stem Cell Pipeline DevelopmentMar 30, 2016
  • MSB Accelerates Plans for Commercial Manufacturing OperationMar 30, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer